S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:HOTH

Hoth Therapeutics - HOTH Stock Forecast, Price & News

$4.94
+0.01 (+0.20%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.81
▼
$5.05
50-Day Range
$2.96
▼
$10.72
52-Week Range
$2.61
▼
$40.74
Volume
47,140 shs
Average Volume
100,711 shs
Market Capitalization
$7.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.50
HOTH stock logo

About Hoth Therapeutics (NASDAQ:HOTH) Stock

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Receive HOTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOTH Stock News Headlines

January 25, 2023 | finance.yahoo.com
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
December 30, 2022 | benzinga.com
Thinking about buying stock in Mullen Automotive, Hoth Therapeutics, Futu Holdings, Shaw Communications, or Ardelyx?
February 5, 2023 | Wall Street Watch Dogs (Ad)
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
December 30, 2022 | nasdaq.com
Hoth Therapeutics Rises On FDA Accepting IND For Its HT-001 Therapeutic
December 30, 2022 | marketwatch.com
Hoth Therapeutics Shares Double, FDA Accepts New Drug Application for Skin Treatment
December 30, 2022 | msn.com
Why Hoth Therapeutics Shares Are Nosediving
December 30, 2022 | marketwatch.com
Hoth Therapeutics Shares Drop 26% on Discounted Private Share Placement
December 30, 2022 | msn.com
EF Hutton Maintains Buy Rating for Hoth Therapeutics: Here's What You Need To Know
February 5, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
December 29, 2022 | msn.com
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
December 29, 2022 | finance.yahoo.com
FDA Signs Off Hoth Therapeutics' Trial Application For HT-001 For Skin Cancers
December 29, 2022 | msn.com
Hoth Therapeutics surges 35% on FDA nod to begin trial of treatment for skin disorders in cancer patients
December 29, 2022 | marketwatch.com
Hoth Therapeutics Shares Rise 77% After FDA Accepts IND for HT-001
December 29, 2022 | markets.businessinsider.com
Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders
December 29, 2022 | finance.yahoo.com
Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
December 1, 2022 | finance.yahoo.com
Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001
November 9, 2022 | finance.yahoo.com
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
November 1, 2022 | investorplace.com
Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?
October 31, 2022 | msn.com
What's Going On With Hoth Therapeutics Stock?
October 31, 2022 | marketwatch.com
Hoth Therapeutics Shares Rise 30% After Positive Data for BioLexa Trial
October 31, 2022 | finance.yahoo.com
HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS
October 31, 2022 | finance.yahoo.com
Hoth Therapeutics' Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump
October 25, 2022 | msn.com
Why Crown Holdings Shares Are Trading Lower By Around 22%? Here Are 46 Stocks Moving In Tuesday's Mid-Day Session
October 25, 2022 | msn.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.07%
October 25, 2022 | msn.com
US Futures Mixed Ahead of Consumer Confidence, House Price Data
October 24, 2022 | marketwatch.com
Hoth Therapeutics Shares Fall 20% After Reverse-Split News
October 24, 2022 | finance.yahoo.com
Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022
See More Headlines
Receive HOTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOTH Company Calendar

Last Earnings
11/10/2022
Today
2/04/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOTH
CUSIP
N/A
CIK
1711786
Web
www.hoththerapeutics.com
Phone
(646) 756-2997
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$66.50
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+1,246.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($10.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-121.00%
Return on Assets
-108.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.43
Quick Ratio
9.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.31 per share
Price / Book
0.48

Miscellaneous

Outstanding Shares
1,440,000
Free Float
1,286,000
Market Cap
$7.11 million
Optionable
Not Optionable
Beta
0.08

Key Executives

  • Robbie Knie
    Chairman, President & Chief Executive Officer
  • Hayley Springer
    Vice President-Operations
  • David S. Briones
    Chief Financial & Accounting Officer
  • Stefanie Johns
    Chief Scientific Officer
  • MaryBeth Jones
    Director-Project Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HOTH Stock - Frequently Asked Questions

Should I buy or sell Hoth Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOTH shares.
View HOTH analyst ratings or view top-rated stocks.

What is Hoth Therapeutics' stock price forecast for 2023?

1 brokers have issued 1-year price objectives for Hoth Therapeutics' stock. Their HOTH share price forecasts range from $33.00 to $100.00. On average, they predict the company's stock price to reach $66.50 in the next twelve months. This suggests a possible upside of 1,246.2% from the stock's current price.
View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts.

How have HOTH shares performed in 2023?

Hoth Therapeutics' stock was trading at $7.80 at the start of the year. Since then, HOTH shares have decreased by 36.7% and is now trading at $4.94.
View the best growth stocks for 2023 here.

When is Hoth Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our HOTH earnings forecast.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its earnings results on Thursday, November, 10th. The company reported ($2.05) earnings per share for the quarter.

When did Hoth Therapeutics' stock split?

Shares of Hoth Therapeutics reverse split on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

How do I buy shares of Hoth Therapeutics?

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $4.94.

How much money does Hoth Therapeutics make?

Hoth Therapeutics (NASDAQ:HOTH) has a market capitalization of $7.11 million. The company earns $-14,310,000.00 in net income (profit) each year or ($10.55) on an earnings per share basis.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The official website for the company is www.hoththerapeutics.com. The company can be reached via phone at (646) 756-2997 or via email at investorrelations@hoththerapeutics.com.

This page (NASDAQ:HOTH) was last updated on 2/5/2023 by MarketBeat.com Staff